« Back
Home /
Sciadopitysin

Sciadopitysin

Item no.	TMO-T5S2129-1mg
Manufacturer	TargetMol
CASRN	521-34-6
Amount	1 mg
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 25 mg 2 mg 500 mg 50 mg 5 mg
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Purity	0,9867
Citations	1.Choi EM, et al.Sciadopitysin alleviates methylglyoxal-mediated glycation in osteoblastic MC3T3-E1 cells by enhancing glyoxalase system and mitochondrial biogenesis.Free Radic Res. 2014 Jul;48(7):729-39.
Smiles	COc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)c(-c3cc(ccc3OC)-c3cc(=O)c4c(O)cc(OC)cc4o3)c2o1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Shipping Condition	Cool pack
Available
Manufacturer - Targets	NF-κB\|\|\|TNF
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	580.54
Description	Sciadopitysin may prevent the development of diabetic osteopathy, it exerts its therapeutic effects via upregulation of mitochondrial biogenesis.Sciadopitysin shows protective effects on antimycin A-induced toxicity in osteoblastic MC3T3-E1 cells, it may reduce or prevent osteoblasts degeneration.Sciadopitysin can inhibit the Aβ aggregation and reduce Aβ-induced toxicity in the primary cortical neurons.
Pathways	NF-κB\|\|\|Apoptosis

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T5S2129-1mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question